- Home
- MNDY vs PRAX Comparison
MNDY vs PRAX Comparison
Compare MNDY & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNDY | PRAX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 7.2B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MNDY | PRAX |
|---|---|---|
| Price | $132.81 | $297.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 24 | 13 |
| Target Price | $265.42 | ★ $397.85 |
| AVG Volume (30 Days) | ★ 1.2M | 569.5K |
| Earning Date | 02-09-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 192.87 | N/A |
| EPS | ★ 1.23 | N/A |
| Revenue | ★ $1,166,095,000.00 | $7,463,000.00 |
| Revenue This Year | $28.81 | N/A |
| Revenue Next Year | $21.41 | $14,827.76 |
| P/E Ratio | $106.31 | ★ N/A |
| Revenue Growth | 28.62 | ★ 364.98 |
| 52 Week Low | $129.99 | $26.70 |
| 52 Week High | $342.64 | $317.72 |
Technical Indicators
Market Signals| Indicator | MNDY | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 32.72 | 61.96 |
| Support Level | $129.77 | $266.93 |
| Resistance Level | $147.39 | $306.16 |
| Average True Range (ATR) | 5.51 | 16.10 |
| MACD | -0.86 | -2.70 |
| Stochastic Oscillator | 14.32 | 60.78 |
Price Performance
Historical ComparisonAbout MNDY monday.com Ltd.
Monday.com is a work management platform allowing for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2024, the company had over 245,000 customers.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.